within Pharmacolibrary.Drugs.ATC.L;

model L01CE04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.07383333333333333,
    adminDuration  = 600,
    adminMass      = 0.0005,
    adminCount     = 1,
    Vd             = 0.0366,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Belotecan is a semi-synthetic camptothecin analogue and a topoisomerase I inhibitor, mainly developed for the treatment of various cancers including small cell lung cancer and ovarian cancer. It has been approved for clinical use in South Korea but is not widely approved or used globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were obtained from adult cancer patients (primarily with lung or ovarian cancer), following intravenous administration of belotecan.</p><h4>References</h4><ol><li><p>Lee, S, et al., &amp; Kim, HS (2025). Pharmacokinetics, toxicities, and tissue concentrations of belotecan sprayed by rotational intraperitoneal pressurized aerosol chemotherapy in a pig model. <i>Journal of gynecologic oncology</i> 36(3) e37–None. DOI:<a href=&quot;https://doi.org/10.3802/jgo.2025.36.e37&quot;>10.3802/jgo.2025.36.e37</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39575997/&quot;>https://pubmed.ncbi.nlm.nih.gov/39575997</a></p></li><li><p>Jin, QR, et al., &amp; Shim, CK (2009). Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 39(10) 711–721. DOI:<a href=&quot;https://doi.org/10.1080/00498250903026458&quot;>10.1080/00498250903026458</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19552531/&quot;>https://pubmed.ncbi.nlm.nih.gov/19552531</a></p></li><li><p>Wu, H, et al., &amp; Zamboni, WC (2012). Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. <i>Journal of clinical pharmacology</i> 52(2) 180–194. DOI:<a href=&quot;https://doi.org/10.1177/0091270010394851&quot;>10.1177/0091270010394851</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21233302/&quot;>https://pubmed.ncbi.nlm.nih.gov/21233302</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01CE04;
